US$ 26.64
foxo4 dri senolytic peptide human trial 2024 2025 FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Targeting Cellular Senescence in Aging
Description
Erythropoietins (EPO)

[PubMed: 2918060] 47

It never touches the liver on its first pass

Hormonal Balance Hormone Regulation: Peptide Therapy helps maintain optimal hormone levels according to age, particularly growth hormone (GH)

1 yrCN 18% Reorder rate 91 Interested customers 3/3 Matches all BSTBIO Cosmetic Grade CAS 49557-75-7 AHK-Cu GHK-Cu Copper Peptide Powder 99% Copper Tripeptide-1 $7.50-10.50 Min
S7)):161165
